Targeting STAT4 in systemic sclerosis: A promising new direction

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 445-448

  Barnes, Jammie ^a   Agarwal, Sandeep K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

dermal fibrosis; STAT4; systemic sclerosis

Indexed keywords

BLEOMYCIN; STAT4 PROTEIN;

ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

EID: 79960930749     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.31     Document Type: Article

References (22)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367(9523), 1683-1691 (2006) (Pubitemid 43728250)
2. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 20(4), 975-984 (1977)
3. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr. Opin. Rheumatol. 18(6), 579-581 (2006) (Pubitemid 44607409)
4. Gourh P, Arnett FC, Assassi S et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res. Ther. 11(5), R147 (2009)
5. Tan FK, Zhou X, Mayes MD et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45(6), 694-702 (2006) (Pubitemid 43985337)
6. Agarwal SK. The genetics of systemic sclerosis. Discov Med 10(51), 134-143 (2010)
7. Nishikomori R, Usui T, Wu CY, Morinobu A, OShea JJ, Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R + 2 chain expression and signaling. J Immunol. 169(8), 4388-4398 (2002) (Pubitemid 35178213)
8. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, OShea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202, 139-156 (2004) (Pubitemid 39576910)
9. Remmers EF, Plenge RM, Lee AT et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J. Med 357(10), 977-986 (2007) (Pubitemid 47367077)
10. Rueda B, Broen J, Simeon C et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol. Genet. 18(11), 2071-2077 (2009)
11. Avouac J, Furnrohr BG, Tomcik M et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 63(3), 800-809 (2011)
12. Dieude P, Guedj M, Wipff J et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 60(8), 2472-2479 (2009)
13. Gourh P, Agarwal SK, Divecha D et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 60(12), 3794-3806 (2009)
14. Tsuchiya N, Kawasaki A, Hasegawa M et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum. Dis. 68(8), 1375-1376 (2009)
15. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 42(5), 426-429 (2010)
16. Mavalia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol. 151(6), 1751-1758 (1997) (Pubitemid 27527937)
17. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor a, and interferon-g levels in sera from patients with scleroderma. Arthritis Rheum. 35(1), 67-72 (1992)
18. Molteni M, Della BS, Mascagni B et al. Increased interferon-gamma (IFN-g) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynauds phenomenon. Clin Exp. Immunol. 116(1), 164-168 (1999) (Pubitemid 29170020)
19. Dieude P, Guedj M, Wipff J et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 60(1), 225-233 (2009)
20. Farina GA, York MR, Di MM et al. Poly(I:C) drives type I IFN-and TGFb-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest. Dermatol. 130, 2583-2593 (2010)
21. Agarwal SK, Wu M, Livingston CK et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther. 13(1), R3 (2011)
22. Tyler DR, Persky ME, Matthews LA, Chan S, Farrar JD. Pre-assembly of STAT4 with the human IFN-a/b receptor-2 subunit is mediated by the STAT4 N-domain. Mol. Immunol. 44(8), 1864-1872 (2007)